Novel therapy for children with chronic hormone deficiency provides lifeline for parents
- Alkindi® is the first replacement therapy specially designed for infants, children and adolescents with paediatric adrenal insufficiency
- Adrenal insufficiency is caused by a lack of the stress hormone cortisol – which can be fatal
- This new therapy, which has been developed by University of Sheffield spin-out company Diurnal, has been granted market authorisation by the European Medicine Agency.
Recent Blog Posts
Liquid Hydrocortisone Discontinued in the UK
Liquid hydrocortisone injections have been discontinued in the UK, affecting emergency treatment for people with adrenal insufficiency. This follows the supply shortage reported in February 2025 -...
Medicine security – a national UK priority.
Concerns about medicines shortages in the UK have been highlighted in recent analysis from the House of Lords Public Services Committee and the Royal Pharmaceutical Society. The House of Lords Public Services Committee warns that medicines supply should be treated as...
2026 CAH Support Group Conference, 28th June, Sheffield
SUNDAY 28th JUNE 2026 9.30 -16:00 The Old Rectory, Handsworth, Sheffield, S13 9BZ theoldrectoryhandsworth.co.uk Those living with CAH and their families and friends are invited to the biennial conference of CAH Support Group. Visit our online booking page here to find...